Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 11

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 11
---
, the number of Common Stock Warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold. |
| Shares of Common Stock outstanding before the offering |     | 963,796 Shares of Common Stock as of the date hereof (not including shares issuable upon exercisable warrants).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Offering Price                                         |     | $            per share of Common Stock and accompanying Common Stock Warrants, or pre-funded warrants and accompanying Common Stock Warrants, as applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Common Stock outstanding after this offering           |     | Shares (assuming we sell only shares of common stock and no pre-funded warrants, and none of the Common Stock Warrants issued in this offering are exercised).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Use of proceeds                                        |     | We estimate that we will receive net proceeds from this offering of approximately $            based upon an assumed offering price of $            per share of Common Stock and accompanying Common Stock Warrants, or pre-funded warrant and accompanying Common Stock Warrants, as applicable, which was also the last reported trading price of our common stock on The Nasdaq Capital Market on April    , 2025, after deducting Placement Agent fees and estimated offering expenses payable by us. We currently intend to use the net proceeds we receive from this offering to further the development of our Product Candidates including the (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

4

Risk Factors Summary In evaluating the information in this prospectus, you should carefully read this prospectus, including the annexes, and especially consider the factors discussed in the section titled “ Risk Factors.” Some of the risks related to Revelation’s business and industry are summarized below. Risks Related to Our Business •We have a limited operating history and no products approved for commercial sale. We have incurred net losses since our inception, we anticipate that we will continue to incur significant losses for the foreseeable future, and even if we were to generate revenue, we may never achieve or maintain profitability. Risks Related to the Product Development, Regulatory Approval, Manufacturing and Commercialization of Our Program Products and Product Candidates •If preclinical studies or clinical studies for our Program Products are unsuccessful or delayed, we will be unable